Lantern Pharma is trading at $2.64 (5.7% down) as investors lock in gains following a multi-day rally tied to the company's AI-related spin-out.
- The decline appears consistent with normal post-rally volatility and thinner after-hours liquidity rather than a new fundamental development.
- There is no fresh company-specific news or earnings release cited after the market close to account for the move.